000147814 001__ 147814
000147814 005__ 20250109150036.0
000147814 0247_ $$2doi$$a10.1038/jid.2014.487
000147814 0248_ $$2sideral$$a129716
000147814 037__ $$aART-2015-129716
000147814 041__ $$aeng
000147814 100__ $$aSandoval, Juan
000147814 245__ $$aMicroRNA expression profiling and DNA methylation signature for deregulated MicroRNA in cutaneous T-Cell Lymphoma
000147814 260__ $$c2015
000147814 5203_ $$aMicroRNAs usually regulate gene expression negatively, and aberrant expression has been involved in the development of several types of cancers. Microarray profiling of microRNA expression was performed to define a microRNA signature in a series of mycosis fungoides tumor stage (MFt, n=21) and CD30+ primary cutaneous anaplastic large cell lymphoma (CD30+ cALCL, n=11) samples in comparison with inflammatory dermatoses (ID, n=5). Supervised clustering confirmed a distinctive microRNA profile for cutaneous T-cell lymphoma (CTCL) with respect to ID. A 40 microRNA signature was found in MFt including upregulated onco-microRNAs (miR-146a, miR-142-3p/5p, miR-21, miR-181a/b, and miR-155) and downregulated tumor-suppressor microRNAs (miR-200ab/429 cluster, miR-10b, miR-193b, miR-141/200c, and miR-23b/27b). Regarding CD30+ cALCL, 39 differentially expressed microRNAs were identified. Particularly, overexpression of miR-155, miR-21, or miR-142-3p/5p and downregulation of the miR-141/200c clusters were observed. DNA methylation in microRNA gene promoters, as expression regulatory mechanism for deregulated microRNAs, was analyzed using Infinium 450K array and approximately one-third of the differentially expressed microRNAs showed significant DNA methylation differences. Two different microRNA methylation signatures for MFt and CD30+ cALCL were found. Correlation analysis showed an inverse relationship for microRNA promoter methylation and microRNA expression. These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients.
000147814 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000147814 590__ $$a6.915$$b2015
000147814 591__ $$aDERMATOLOGY$$b1 / 61 = 0.016$$c2015$$dQ1$$eT1
000147814 592__ $$a2.66$$b2015
000147814 593__ $$aBiochemistry$$c2015$$dQ1
000147814 593__ $$aMolecular Biology$$c2015$$dQ1
000147814 593__ $$aDermatology$$c2015$$dQ1
000147814 593__ $$aCell Biology$$c2015$$dQ1
000147814 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000147814 700__ $$aDíaz-Lagares, Angel
000147814 700__ $$aSalgado, Rocío
000147814 700__ $$aServitje, Octavio
000147814 700__ $$aCliment, Fina
000147814 700__ $$aOrtiz-Romero, Pablo L.
000147814 700__ $$aPérez-Ferriols, Amparo
000147814 700__ $$0(orcid)0000-0003-2078-8205$$aGarcia-Muret, Maria P.
000147814 700__ $$aEstrach, Teresa
000147814 700__ $$aGarcia, Mar
000147814 700__ $$aNonell, Lara
000147814 700__ $$aEsteller, Manel
000147814 700__ $$aPujol, Ramon M.
000147814 700__ $$aEspinet, Blanca
000147814 700__ $$aGallardo, Fernando
000147814 773__ $$g135, 4 (2015), 1128-1137$$pJ. invest. dermatol.$$tJOURNAL OF INVESTIGATIVE DERMATOLOGY$$x0022-202X
000147814 8564_ $$s3432155$$uhttps://zaguan.unizar.es/record/147814/files/texto_completo.pdf$$yVersión publicada
000147814 8564_ $$s3339478$$uhttps://zaguan.unizar.es/record/147814/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000147814 909CO $$ooai:zaguan.unizar.es:147814$$particulos$$pdriver
000147814 951__ $$a2025-01-09-14:59:11
000147814 980__ $$aARTICLE